CKPT Stock Overview A clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. More details
Rewards Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Checkpoint Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Checkpoint Therapeutics Historical stock prices Current Share Price US$3.29 52 Week High US$4.50 52 Week Low US$1.38 Beta 1.32 1 Month Change -18.56% 3 Month Change 48.20% 1 Year Change 34.84% 3 Year Change -88.12% 5 Year Change -79.04% Change since IPO -93.42%
Recent News & Updates
New minor risk - Share price stability Dec 23
President recently sold US$3.1m worth of stock Dec 23
Checkpoint Therapeutics, Inc. Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl) Dec 14
Consensus revenue estimates fall by 30% Nov 19
Third quarter 2024 earnings released: US$0.23 loss per share (vs US$0.29 loss in 3Q 2023) Nov 14
Checkpoint Therapeutics, Inc. Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 Sep 16 See more updates
New minor risk - Share price stability Dec 23
President recently sold US$3.1m worth of stock Dec 23
Checkpoint Therapeutics, Inc. Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl) Dec 14
Consensus revenue estimates fall by 30% Nov 19
Third quarter 2024 earnings released: US$0.23 loss per share (vs US$0.29 loss in 3Q 2023) Nov 14
Checkpoint Therapeutics, Inc. Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 Sep 16
Consensus revenue estimates increase by 11% Aug 19
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 13
New minor risk - Share price stability Aug 01
Checkpoint Therapeutics, Inc Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma Jul 26
Price target increased by 19% to US$21.67 Jul 07 Checkpoint Therapeutics, Inc. announced a financing transaction Checkpoint Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.000001 million.
President recently sold US$50k worth of stock Jun 30
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission Jun 24
No longer forecast to breakeven Jun 08
First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.89 loss in 1Q 2023) May 12
Checkpoint Therapeutics, Inc., Annual General Meeting, May 13, 2024 Apr 03
Insufficient new directors Apr 01
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 24
New major risk - Revenue and earnings growth Mar 23
Checkpoint Therapeutics, Inc. Appoints Amit Sharma to Its Board as an Independent, Non-Executive Director Mar 20
Checkpoint Therapeutics, Inc. Receives A Letter from Nasdaq Confirming the Company Was No Longer in Compliance with the Board Independence Rule Feb 04
Checkpoint Therapeutics, Inc. Receives A Letter from Nasdaq Confirming the Company Was No Longer in Compliance with the Board Independence Rule Feb 03
New major risk - Financial position Jan 31
New major risk - Share price stability Jan 30 Checkpoint Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $14.000001 million. Jan 30
Checkpoint Therapeutics, Inc. Announces Board Changes, Effective January 31, 2024 Jan 06
Consensus revenue estimates increase by 25%, EPS downgraded Dec 20
U.S. Food and Drug Administration Issues Complete Response Letter for Checkpoint Therapeutics, Inc.'s Cosibelimab Solely Due to Inspection Findings At Third-Party Manufacturer Dec 19
Consensus revenue estimates increase by 19% Nov 20
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 16
New major risk - Revenue and earnings growth Oct 29
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer Oct 19
First quarter 2023 earnings released: US$0.89 loss per share (vs US$1.98 loss in 1Q 2022) Aug 16
Consensus revenue estimates increase by 41% Aug 15
Price target decreased by 42% to US$33.50 Jul 28
Consensus revenue estimates decrease by 78%, EPS upgraded May 22
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 17
Forecast breakeven date pushed back to 2025 Apr 04
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 02
Price target decreased to US$103 Jan 05
Checkpoint Therapeutics, Inc. Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma Jan 05
Consensus forecasts updated Dec 29
Forecast to breakeven in 2024 Dec 03
Consensus revenue estimates fall by 26% Nov 16
Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.14 loss in 3Q 2021) Nov 10
We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate Sep 20
Checkpoint: Strong Data, But Comes With Risks Sep 08
Consensus forecasts updated Aug 19
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 12
Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M Aug 12
Price target decreased to US$17.60 Jul 14
Checkpoint Therapeutics, Inc. Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma Jun 17
Consensus forecasts updated May 19
Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans? May 18
Checkpoint Therapeutics Inc. Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency May 14
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 13
Checkpoint Therapeutics, Inc., Annual General Meeting, Jun 15, 2022 May 02
Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions Apr 18
Consensus forecasts updated Apr 04
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 29
CFO, Corporate Secretary & Treasurer recently sold US$72k worth of stock Mar 12
Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth Feb 15
CFO, Corporate Secretary & Treasurer recently sold US$93k worth of stock Feb 03
Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results Jan 28
Forecast to breakeven in 2024 Jan 28
Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma Jan 26
Checkpoint Therapeutics, Inc. Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Dec 09
Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout Nov 26
Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.087 loss in 3Q 2020) Nov 06
Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans Oct 30
Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.09 loss in 2Q 2020) Aug 08
Consensus revenue estimates fall to US$359.0k Aug 06
We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate Jul 17
Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data Jul 14 Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from Russell 3000E Index
Checkpoint Therapeutics (CKPT) Investor Presentation - Slideshow Jun 21
Price target increased to US$15.80 Jun 11
Checkpoint surges 24% on B. Riley buy initiation, 567% upside potential Jun 09
It's Unlikely That Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Will See A Huge Pay Rise This Year Jun 02
Checkpoint Therapeutics, Inc. Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma May 13
First quarter 2021 earnings released: US$0.093 loss per share (vs US$0.064 loss in 1Q 2020) May 09
Full year 2020 earnings released: US$0.34 loss per share (vs US$0.70 loss in FY 2019) Mar 11
Earnings beat expectations, revenue disappoints Mar 11
The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 141% And Shareholders Are Boasting About It Mar 11 Shareholder Returns CKPT US Biotechs US Market 7D -6.5% -2.3% -2.6% 1Y 34.8% -6.3% 24.5%
See full shareholder returns
Return vs Market: CKPT exceeded the US Market which returned 24.5% over the past year.
Price Volatility Is CKPT's price volatile compared to industry and market? CKPT volatility CKPT Average Weekly Movement 10.7% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.7% 10% least volatile stocks in US Market 3.1%
Stable Share Price: CKPT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CKPT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company’s lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Show more Checkpoint Therapeutics, Inc. Fundamentals Summary How do Checkpoint Therapeutics's earnings and revenue compare to its market cap? CKPT fundamental statistics Market cap US$156.26m Earnings (TTM ) -US$46.47m Revenue (TTM ) US$47.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CKPT income statement (TTM ) Revenue US$47.00k Cost of Revenue US$27.64m Gross Profit -US$27.59m Other Expenses US$18.87m Earnings -US$46.47m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.95 Gross Margin -58,712.77% Net Profit Margin -98,868.09% Debt/Equity Ratio 0%
How did CKPT perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 00:19 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Checkpoint Therapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mayank Mamtani B. Riley Securities, Inc. Justin Walsh B. Riley Securities, Inc. Jonathan Aschoff B. Riley Wealth
Show 4 more analysts 
